Transcriptional Regulation of CYP2E1: Promoter Methylation in In Vitro Models and Human Liver Disease Samples
Genes · 2025
DOI: 10.3390/genes16080990 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Nina Komaniecka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111 Szczecin, Poland. Hauptthemen laut MEDLINE: DNA Methylation, Promoter Regions, Genetic, Cytochrome P-450 CYP2E1, Liver Diseases. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre.
Abstract (Originalsprache)
Background/Objectives: DNA methylation is a critical epigenetic mechanism involved in gene expression regulation. This study examines promoter methylation of CYP2E1 in healthy liver, intestinal mucosa, as well as pathological liver samples, alongside in in vitro cell models.
Methods
First, in tissue samples from the liver, duodenum, jejunum, and colon of healthy organ donors, CYP2E1 promoter methylation was quantified using the EpiTect Methyl II PCR System, while gene expression was determined by quantitative real-time PCR. Then, in vitro experiments were performed using HepG2 and Caco-2 cell lines. Cells were treated with 5-Aza-2′-deoxycytidine to induce demethylation, with subsequent analysis of CYP2E1 mRNA levels. Subsequently, promoter methylation was assessed via pyrosequencing, while gene expression was quantified using quantitative real-time PCR.
Results
The analysis revealed statistically significant differences in the methylation patterns of the CYP2E1 promoter between healthy liver and gastrointestinal tissues. In cell lines, treatment with 5-Aza-2′-deoxycytidine resulted in increased CYP2E1 mRNA levels and demonstrated a strong negative correlation between promoter methylation and gene expression. However, in liver disease samples, differential methylation did not consistently translate into decreased CYP2E1 expression.
Conclusions
Although in vitro experiments support a regulatory role of promoter methylation in controlling CYP2E1 expression, the clinical data indicate that additional factors may contribute to gene regulation in liver pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111 Szczecin, Poland.
- Laboratory of Pharmacodynamics, Pomeranian Medical University in Szczecin, 71-899 Szczecin, Poland.
- Department of General and Transplant Surgery, Pomeranian Regional Hospital, 71-455 Szczecin, Poland.
- Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, 70-111 Szczecin, Poland.
ORCID-Profile: Nina Komaniecka, Joanna Łapczuk-Romańska, Marek Droździk
Förderung
- National Science Centre
Zitieren
APA
Komaniecka, N., Kurzawski, M., Szeląg-Pieniek, S., Łapczuk-Romańska, J., Post, M., Adamiak-Giera, U., & Droździk, M. (2025). Transcriptional Regulation of CYP2E1: Promoter Methylation in In Vitro Models and Human Liver Disease Samples. Genes. https://doi.org/10.3390/genes16080990
Vancouver
Komaniecka N, Kurzawski M, Szeląg-Pieniek S, Łapczuk-Romańska J, Post M, Adamiak-Giera U, et al. Transcriptional Regulation of CYP2E1: Promoter Methylation in In Vitro Models and Human Liver Disease Samples. Genes. 2025. doi:10.3390/genes16080990
BibTeX
@article{Komaniecka2025,
author = {Komaniecka, Nina and Kurzawski, Mateusz and Szeląg-Pieniek, Sylwia and Łapczuk-Romańska, Joanna and Post, Mariola and Adamiak-Giera, Urszula and Droździk, Marek},
title = {Transcriptional Regulation of CYP2E1: Promoter Methylation in In Vitro Models and Human Liver Disease Samples},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16080990}
}
EUVIMED